MaaT Pharma’s PHOEBUS Trial Moves Ahead with Strong Safety Endorsement

MaaT Pharma’s groundbreaking Phase 2b PHOEBUS trial, focused on its microbiome therapy MaaT033, has received a green light to continue without changes after a routine safety review by an independent Data Safety Monitoring Board (DSMB). The review, based on data from 59 patients, confirmed that MaaT033 is well tolerated and exhibits an acceptable safety profile. With 80 patients enrolled across six European countries by the end of 2024, the trial is making significant strides toward its target of 387 participants, aiming to explore MaaT033 as a novel adjunctive treatment for cancer patients undergoing Allo-HSCT.

“We are pleased with the positive safety results and the steady progress of patient enrollment,” said Dr. Gianfranco Pittari, Chief Medical Officer of MaaT Pharma. With ongoing recruitment across 54 clinical sites, this international, double-blind study sets the stage for advancing microbiome-driven immunotherapies in oncology. Upcoming milestones include further safety and mortality assessments in 2025, as the company works to validate its innovative approach to improving survival outcomes for cancer patients.